SCHEMBL5451482

SCHEMBL5451482

COc1ccc(Cl)cc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ncccc3C)CC2)nc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 8/20 0.58
MAPT P10636 2/20 0.52
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 3/20 0.50
TRPV1 Q8NER1 2/20 0.50
USP2 O75604 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
GFER P55789 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
IGF1R P08069 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 1/20 0.47
CNR1 P21554 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PANK3 Q9H999 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473516 0.84 MAPT (0.54) RBP4MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL5465924 0.83 KDM4E (0.46) MAPTALDH1A1KDM4ETRPV1USP2
SCHEMBL5473181 0.82 RBP4 (0.47) RBP4MAPTALDH1A1KDM4ETRPV1
SCHEMBL5463477 0.82 TRPV1 (0.53) RBP4MAPTALDH1A1TRPV1SMN1; SMN2
SCHEMBL5464794 0.81 GFER (0.59) RBP4MAPTALDH1A1KDM4ETRPV1
SCHEMBL5467111 0.81 MAPT (0.51) RBP4MAPTALDH1A1KDM4ETRPV1
SCHEMBL5460059 0.80 MAPT (0.50) RBP4MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL5465645 0.79 CNR1 (0.52) MAPTKDM4EIGF1RRAB9ACNR1
SCHEMBL5459635 0.79 MAPK1 (0.51) MAPTALDH1A1KDM4ETRPV1TSHR
SCHEMBL16690815 0.78 MAPT (0.78) RBP4MAPTALDH1A1KDM4ETRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 RBP4 2001/4885MAPT 758/4885ALDH1A1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.